-
Announcement of National Medical Products Administration and National Intellectual Property Administration on the Issuance of the Measures for the Implementation of the Mechanism for Early Settlement of Drug Patent Disputes (Interim)
2021-07-04
The National Medical Products Administration and the China National Intellectual Property Administration formulated the Measures for the Implementation of the Mechanism for Early Settlement of Drug Patent Disputes (interim).
-
NMPA Announcement on Issuing the Catalogue of Reference Preparations of Generic Drugs (Forty-two Batch)
2021-06-25
On June 22, the Catalogue of Reference Preparations of Generic Drugs (Forty-two Batch) was issued, upon review and determination by the NMPA Experts Committee of Quality and Efficacy Consistency Evaluation of Generic Drugs.
-
NMPA Announcement on the Revision of the Package Insert of Somatostatin for Injection
2021-06-24
The NMPA decided to modify the items of [Adverse reactions],[Precautions] and [Drug Interactions] in the package inserts of somatostatin for injection.
-
NMPA Announcement on the Revision of the Package Insert of the Oxiracetam Preparations
2021-06-24
The NMPA decided to modify the items of [Adverse reactions], [Contraindications] and [Precautions] in the package inserts of oxiracetam preparations. On June 22, relevant issues are hereby announced as follows.
-
NMPA Announcement on Issuing the Requirements for Change Items and Application Dossiers of Marketed Biological Products
2021-06-18
The NMPA has organized to formulate the Requirements for Change Items and Application Dossiers of Marketed Biological Products, which has been issued and implemented on June 17.
-
NMPA Announcement on Revising the Package Insert of Misoprostol Tablets for Obstetrical and Gynecological Application
2021-02-26
To further protect public medication safety, the NMPA decided to revise the package insert of Misoprostol Tablets for obstetrical and gynecological application. Relevant issues are hereby announced as follows.
